27,111 results match your criteria Granulocytopenia


Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia.

Med Sci Monit 2020 Jul 3;26:e923271. Epub 2020 Jul 3.

Department of Pediatrics, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China (mainland).

BACKGROUND B cell acute lymphoblastic leukemia (B-ALL) is the most common type of ALL. This study aimed to explore risk factors for relapse of childhood B-ALL. MATERIAL AND METHODS Total of 102 pediatric B-ALL patients were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.923271DOI Listing

The impact of COVID-19 on ischemic stroke.

Diagn Pathol 2020 Jun 29;15(1):78. Epub 2020 Jun 29.

Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, China.

Background: The outbreak of a novel coronavirus since December 2019, became an emergency of major international concern. As of June 21, 2020, the SARS-CoV-2 pandemic has caused 8,769,844 confirmed infections with 463,745 fatal cases worldwide. The SARS-CoV-2 outbreak is a major challenge for clinicians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-020-00994-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323364PMC

[Agranulocytosis after use of metamizole - an underestimated risk?]

Laryngorhinootologie 2020 Jun 25. Epub 2020 Jun 25.

Hals-Nasen-Ohren-Klinik, Kopf- und Halschirurgie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Objective:  Metamizole was the second most common drug prescribed in Germany in 2018 despite the known risk of agranulocytosis and the strict indication. According to Stammschulte et al. up to 25 % of all prescriptions are off-label use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1190-4445DOI Listing

Metamizole-induced reactions as a paradigm of drug hypersensitivity: Non-allergic reactions, anaphylaxis, and delayed-type allergy.

Clin Exp Allergy 2020 Jun 21. Epub 2020 Jun 21.

Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cea.13689DOI Listing

[Distribution and Drug Sensitivity of Pathogens Causing Nosocomial Infection in Patients with Hematological Granulocytosis].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Jun;28(3):989-995

Department of Hematology, The First Hospital of Lanzhou University, Lnazhou 730000, Gansu Province, China,E-mail:

Objective: To investigate the distribution and drug resistance of nosocomial infection pathogens in AL patients with hematological agranulocytosis, so as to provide evidence for the clinical rational use of antibiotics.

Methods: Pathogenic data of 504 hospitalized patients with agranulocytosis caused by nosocomial infection in the Department of Hematology, the First Hospital of Lanzhou University from May 2015 to May 2018 were collected and retrospectively analyzed for the distribution of pathogenic bacteria and the results of drug susceptibility.

Results: The isolated pathogenic bacteria strains amounted to 184, out of which, 168 strains (91. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.03.045DOI Listing

Effective Preoperative Plasmapheresis Treatment of Severe Hyperthyroidism in a Patient with Giant Toxic Nodular Goiter and Methimazole-Induced Agranulocytosis.

Medicina (Kaunas) 2020 Jun 12;56(6). Epub 2020 Jun 12.

Collegium Medicum, Jan Kochanowski University, IX Wieków Kielc Av.19, 25-319 Kielce, Poland.

Agranulocytosis is a rare but very serious complication of thyrostatic therapy. In severe hyperthyroidism, the removal of circulating thyroid hormones by plasmapheresis may be an effective therapeutic option. This report describes the therapeutic difficulties and successful preoperative treatment with plasmapheresis in a 63-year-old patient admitted to the Endocrinology Clinic with severe hyperthyroidism, during the course of giant toxic nodular goiter and agranulocytosis, which occurred after 2 weeks of taking methimazole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medicina56060290DOI Listing

[Development and implementation of clozapine protocol in patients with schizophrenia in Greece].

Psychiatriki 2020 Jan-Mar;31(1):70-81

Department of Psychiatry, Aghioi Anargyroi Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Clozapine is an atypical antipsychotic used for the treatment of resistant schizophrenia, exhibiting significant advantages over other antipsychotic agents. Clozapine efficacy is well established in people diagnosed with schizophrenia via reducing both positive and negative symptoms. Also, is associated with a low risk of extrapyramidal side effects compared to other antipsychotics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22365/jpsych.2020.311.70DOI Listing

Management of clozapine treatment during the COVID-19 pandemic.

Ther Adv Psychopharmacol 2020 27;10:2045125320928167. Epub 2020 May 27.

Pharmacy Department, South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK.

Clozapine is the only available treatment for refractory schizophrenia but its use involves frequent physical contact with healthcare workers for the purpose of mandatory blood monitoring. During the COVID-19 pandemic, patients taking clozapine will be self-isolating to reduce the risk of infection, not least because these patients are at high risk of serious illness and fatality because of high rates of diabetes, obesity and pulmonary disease and an increased risk of pneumonia. Problems may also arise because both clozapine-induced myocarditis and neutropenic sepsis share signs and symptoms with COVID-19 (fever, chest pain, dyspnoea, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2045125320928167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256815PMC

Preoperative plasmapheresis experience in Graves' disease patients with anti-thyroid drug-induced hepatotoxicity.

Transfus Apher Sci 2020 Jun 2:102826. Epub 2020 Jun 2.

Marmara University School of Medicine, Department of Endocrinology and Metabolism, Istanbul, Turkey. Electronic address:

Hepatotoxicity is a rare but serious side effect of antithyroid drug (ATI) therapy in Graves' disease patients. Cessation of ATI drug is needed in most of the patients if liver enzymes highly elevated or in case of agranulocytosis. Permanent therapy, surgery or radioactive iodine ablation are the treatment choices to ensure euthyroidism in active Graves' disease patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2020.102826DOI Listing

Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients.

J Clin Med 2020 Jun 10;9(6). Epub 2020 Jun 10.

Service de Médecine Interne, Diabètes et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Agranulocytosis is a rare, but serious and life-threatening hematologic disorder in elderly patients. Idiosyncratic drug-induced agranulocytosis (IDIA) has been classically defined by a neutrophil count below 0.5 × 10/L. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9061808DOI Listing

Association of MICA gene polymorphisms with thionamide-induced agranulocytosis.

J Endocrinol Invest 2020 Jun 9. Epub 2020 Jun 9.

Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.

Background: Thionamide-induced agranulocytosis (TIA), namely antithyroid drug (ATD)-induced agranulocytosis, is one of the most feared adverse effect of ATDs. It is defined as a granulocyte count of less than 0.5 × 10/L after ATD administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40618-020-01319-0DOI Listing

Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide.

BMC Psychiatry 2020 Jun 5;20(1):279. Epub 2020 Jun 5.

Consultant Forensic Psychiatrist, Ashworth Hospital, Mersey Care NHS Foundation Trust, Parkbourn, Maghull, Merseyside, L31 1HW, UK.

Clozapine remains the only drug treatment likely to benefit patients with treatment resistant schizophrenia. Its use is complicated by an increased risk of neutropenia and so there are stringent monitoring requirements and restrictions in those with previous neutropenia from any cause or from clozapine in particular. Despite these difficulties clozapine may yet be used following neutropenia, albeit with caution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12888-020-02592-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275543PMC

Gene polymorphisms of SOCS1 and SOCS2 and acute lymphoblastic leukemia.

Eur Rev Med Pharmacol Sci 2020 May;24(10):5564-5572

Department of Hematology, Yixing People's Hospital, Yixing, China. staff151yxph.com.

Objective: Acute lymphoblastic leukemia (ALL) causes the dysfunction of the systemic blood system and immune system. The etiology and predisposing factors of ALL are unknown. The suppressor of cytokine signaling 1 (SOCS1) and SOCS2 are inhibitors of cytokine signal transduction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202005_21342DOI Listing

Non-ischemic Cardiomyopathy: A Rare Adverse Effect of Clozapine.

Cureus 2020 Apr 30;12(4):e7901. Epub 2020 Apr 30.

Cardiology, Ascension Borgess Hospital, Kalamazoo, USA.

Clozapine is a dibenzodiazepine antipsychotic used for treatment-resistant schizophrenia. Its association with several side effects such as agranulocytosis, seizure, and insulin resistance is well known. Cardiac side effects such as myocarditis and cardiomyopathy are less common and have been seldom reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263404PMC

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

N Engl J Med 2020 06;382(23):2207-2219

From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).

Background: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.

Methods: We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1915315DOI Listing
June 2020
55.873 Impact Factor

[Psychopharmacotherapy during the COVID-19 pandemic].

Nervenarzt 2020 Jun 2. Epub 2020 Jun 2.

Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland.

In view of the current coronavirus disease 2019 (COVID-19) pandemic, patient care, including that of psychiatric patients, is facing unprecedented challenges. Treatment strategies for mental illness include psychotherapy and psychopharmacological interventions. The latter are associated with a multitude of adverse drug reactions (ADR); however, they may currently represent the preferred treatment due to restrictions regarding patient care (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00115-020-00939-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265158PMC

Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.

Int J Mol Sci 2020 May 30;21(11). Epub 2020 May 30.

Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.

Since myeloproliferative neoplasms (MPN) pose a significant risk for vascular and thrombotic complications, cytoreductive therapies, such as hydroxyurea (HU), interferon (IFN) inhibitors, and Janus kinase (JAK) inhibitors are recommended for patients at high risk. However, these agents also place patients at increased risk for drug-related cutaneous adverse events. Herein, we review the literature on skin toxicity related to the use of drugs for the treatment of MPN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312244PMC

Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.

Parkinsonism Relat Disord 2020 May 25;75:55-62. Epub 2020 May 25.

Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:

There is a considerable overlap between Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB). They present a challenge therapeutically, with regard to morbidity and mortality risk. In particular, symptoms of psychosis in these conditions augur a considerably increased burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2020.05.026DOI Listing

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.

Lancet Haematol 2020 Jun;7(6):e490-e497

Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.

Evaluation of tolerability is increasingly relevant for patients with haematological malignancies treated with chronically administered therapies. Adverse events from these agents might affect the ability of patients to tolerate treatment over time. Conventional toxicity tables that include the incidence of high-grade adverse events, defined by the Common Terminology Criteria for Adverse Events, do not provide information on the time profile of these adverse events or reflect the continuous, lower grade symptomatic toxicities that are particularly relevant to treatment tolerability for patients living with indolent disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30067-3DOI Listing

Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.

Lancet Haematol 2020 Jun;7(6):e469-e478

Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus, Valenzano, Italy.

Background: Transfusion-dependent haemoglobinopathies require lifelong iron chelation therapy with one of the three iron chelators (deferiprone, deferasirox, or deferoxamine). Deferasirox and deferiprone are the only two oral chelators used in adult patients with transfusion-dependent haemoglobinopathies. To our knowledge, there are no randomised clinical trials comparing deferiprone, a less expensive iron chelator, with deferasirox in paediatric patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30100-9DOI Listing

Severe clozapine-induced agranulocytosis: successful treatment with G-CSF and rechallenge of clozapine plus D2 potentiation therapy (amisulpride).

Actas Esp Psiquiatr 2020 03 1;48(2):89-91. Epub 2020 Mar 1.

Servicio de Hematología, Hospital de la Merced, Osuna (Sevilla). España.

View Article

Download full-text PDF

Source
March 2020
0.759 Impact Factor

Nøytropeni ved behandling med antipsykotika.

Tidsskr Nor Laegeforen 2020 May 25;140(8). Epub 2020 May 25.

Neutropenia and agranulocytosis are among the most serious and feared adverse effects of antipsychotic drugs. In affected patients there is a risk of both infection and exacerbation of the underlying psychotic disorder, because neutropenia and agranulocytosis often require discontinuation of the antipsychotic drug therapy. The cause is most likely multifactorial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4045/tidsskr.19.0713DOI Listing

A Patient with Fulminant Myasthenia Gravis is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3.

Intern Med 2020 May 26. Epub 2020 May 26.

Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Japan.

This article describes the first reported case of myasthenia gravis (MG) seropositive for both acetylcholine receptor antibody and low-density lipoprotein receptor-related protein 4 antibody, complicated by autoimmune polyglandular syndrome (APS) type 3. The patient exhibited myasthenic weakness restricted to the ocular muscles and ptosis. Severe clinical deterioration ensued with predominant bulbar symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4708-20DOI Listing

The cost-effectiveness of empirical antibiotic treatments for high-risk febrile neutropenic patients: A decision analytic model.

Medicine (Baltimore) 2020 May;99(20):e20022

Division of Infectious Diseases, Brown University, Warren Alpert Medical School.

Purpose: Febrile neutropenia has a significant clinical and economic impact on cancer patients. This study evaluates the cost-effectiveness of different current empiric antibiotic treatments.

Methods: A decision analytic model was constructed to compare the use of cefepime, meropenem, imipenem/cilastatin, and piperacillin/tazobactam for treatment of high-risk patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254453PMC

Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology.

Br J Clin Pharmacol 2020 May 19. Epub 2020 May 19.

UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA, Australia.

There are few fields of medicine in which the individualisation of medicines is more important than in the area of oncology. Under-dosing can have significant ramifications due to the potential for therapeutic failure and cancer progression; by contrast, over-dosing may lead to severe treatment-limiting side effects, such as agranulocytosis and neutropenia. Both circumstances lead to poor patient prognosis and contribute to the high mortality rates still seen in oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14372DOI Listing

Clozapine-induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine.

Hum Psychopharmacol 2020 May 18. Epub 2020 May 18.

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Objective: To determine the prevalence, background factors, and progression of and recovery from clozapine-induced agranulocytosis in Japan.

Methods: Data on treatment-resistant schizophrenia patients registered with the Clozaril Patient Monitoring Service (CPMS) between July 29, 2009 and January 20, 2016 were extracted. Patients with a neutrophil count <500/mm were defined as having agranulocytosis, and those with a leukocyte count <3,000/mm or a neutrophil count <1,500/mm but not meeting the criteria for agranulocytosis were defined as having leukopenia/neutropenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hup.2739DOI Listing

Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program.

Ment Health Clin 2020 May 7;10(3):70-75. Epub 2020 May 7.

Introduction: In October 2015, the Food and Drug Administration (FDA) instituted an update to the mandatory Risk Evaluation and Mitigation Strategy (REMS) program for clozapine to improve safety monitoring of hematologic events. However, the impact of the clozapine REMS program on reporting of hematologic adverse events has not been quantified.

Methods: We assessed adverse event reports for agranulocytosis, granulocytopenia, leukopenia, and neutropenia from the FDA Adverse Event Reporting System (FAERS) for a 1-year time period before (October 2014 to September 2015, pre-REMS) and after (October 2015 to September 2016, post-REMS) the implementation of the clozapine REMS program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.9740/mhc.2020.05.070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213944PMC

Personalized cancer supportive care in COVID-19 era.

Ann Oncol 2020 07 13;31(7):835-837. Epub 2020 May 13.

Advanced Cancer Research Group, Kirkland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219364PMC

Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.

Mol Neuropsychiatry 2020 Apr 26;5(Suppl 1):1-26. Epub 2018 Sep 26.

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Numerous genetic variants have been shown to be associated with antipsychotic response and adverse effects of schizophrenia treatment. However, the clinical application of these findings is limited. The aim of this narrative review is to summarize the most recent publications and recommendations related to the genetics of antipsychotic treatment and shed light on the clinical utility of pharmacogenetics/pharmacogenomics (PGx). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206586PMC

COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE).

Bull Cancer 2020 Jun 30;107(6):629-632. Epub 2020 Apr 30.

Hôpital Universitaire Robert-Debré AP-HP, Université de Paris, service d'hémato-immunologie pédiatrique, Paris, France.

Since the emergence of the SARS-CoV-2 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. They may have to evolve according to the rapid evolution of knowledge on COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2020.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190519PMC

COVID-19 in Neonates and Infants: Progression and Recovery.

Pediatr Infect Dis J 2020 07;39(7):e140-e142

Respiratory Sciences, University of Leicester, Leicester, United Kingdom.

Between March 10, 2020 and April 17, 2020, of 8/70 (11.4%) SARS-CoV-2 positive infants that presented, 5/8 (63%) developed fever, 4/8 (50%) had lower respiratory tract involvement, 2/8 (25%) had neutropenia and thrombocytosis, and 4/8 infants (50%) were treated for suspected sepsis with broad-spectrum antibiotics. Only 1/8 (13%) required pediatric intensive care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/INF.0000000000002738DOI Listing

METHIMAZOLE-INDUCED AGRANULOCYTOSIS AND SEPSIS: WAS THYROID STORM PRESENT OR JUST BEING MIMICKED?

Acta Endocrinol (Buchar) 2019 Oct-Dec;15(4):522-525

Ponta Grossa State University - Medicine, Ponta Grossa, Brazil.

Introduction: Agranulocytosis induced by thioamides is rare, occurring only in 0.2-0.5% of cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4183/aeb.2019.522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200104PMC

Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With Cancer.

JCO Oncol Pract 2020 Jun 5;16(6):348-349. Epub 2020 May 5.

Department of Medical Oncology, University Hospital of Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00197DOI Listing

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Lancet Haematol 2020 Jun 30;7(6):e456-e468. Epub 2020 Apr 30.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

Background: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.

Methods: In this randomised, open-label, phase 3 study we recruited previously untreated patients with multiple myeloma at 172 academic and community practice centres of the European Myeloma Network. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30099-5DOI Listing

Reporting Patterns of Sialorrhea Comparing Users of Clozapine to Users of Other Antipsychotics: A Disproportionality Analysis Using VigiBase.

J Clin Psychopharmacol 2020 May/Jun;40(3):283-286

From the Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht.

Background: Sialorrhea is a non-life-threatening, but potentially invalidating adverse drug reaction (ADR) in patients using clozapine. In light of the very serious ADRs (agranulocytosis and myocarditis), sialorrhea is at risk to be overlooked by health care professionals. In this study, the sialorrhea reporting patterns of clozapine compared with other antipsychotics were assessed by evaluating differences in relative reporting frequency and reporter type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000001198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188267PMC

[Clinical Features of Nosocomial Infections in Agranulocytosis Patients with Hematological Malignancies and Analysis of Risk Factors].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Apr;28(2):669-676

Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China,E-mail: xiyaming@ 163.com.

Objective: To explore the clinical features and risk factors for nosocomial infections in agranulocytosis patients with hematological malignancies so as to provide basis for clinical prevention and treatment of nosocomial infections.

Methods: The clinical data of 725 patients with agranulocytosis in the First Hospital of Lanzhou University from May 2015 to May 2018 were retrospectively analyzed, including sex, age, primary disease, treatment stage, agranulocytosis degree, agranulocytosis duration, nosocomial infection, infectous site, average length of stay and average days of infection. Univariate analysis (Chi-square test) and multivariate analysis (non-conditional Logistic regression models) were used to analyze the risk factors of nosocomial infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.02.052DOI Listing

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study.

Cancer Manag Res 2020 8;12:2481-2489. Epub 2020 Apr 8.

Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China.

Background: The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer.

Methods: Overall, 45 patients were divided into two groups; 29 patients in the experimental group were treated with trastuzumab combined with FLOT and 16 patients in the control group were treated with FLOT alone. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), tumor regression grade (TRG), surgical margin, side effects, and overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S239420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152553PMC

A case report on clozapine-induced ventricular ectopics: a fatal adverse drug reaction.

J Basic Clin Physiol Pharmacol 2020 Apr 17;31(3). Epub 2020 Apr 17.

Indo Soviet Friendship College of Pharmacy - Pharmacy Practice, Moga, Punjab, India.

Background Clozapine is one of the most efficacious antipsychotic drug used for the treatment-resistant schizophrenia; it is sometimes associated with serious adverse reactions like agranulocytosis, myocarditis, cardiac rhythm disturbances, etc. Case presentation A 30-year-old patient with a primary diagnosis of paranoid schizophrenia (ICD code - F20.05) was on regular prescription for 6 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jbcpp-2019-0339DOI Listing

Consensus statement on the use of clozapine during the COVID-19 pandemic.

J Psychiatry Neurosci 2020 05;45(3):222-223

From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind); the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles); the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer); the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane); the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane); the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll); Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll); the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hassan); the Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK (Howes, MacCabe); the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes); the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes); the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly); the Bronx Westchester Medical Group, New York, NY, USA (Laitman); the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee); the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee); the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen (Nielsen); the Mental Health Service Noord-Holland-Noord, Alkmaar, The Netherlands (Schulte); the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor); the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux); the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler); the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA (Freudenreich); and the Harvard Medical School, Boston, MA, USA (Freudenreich).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1503/jpn.200061DOI Listing

[Incidental finding of leukopenia - directly to the hematologist?]

MMW Fortschr Med 2020 Apr;162(7):38-41

Labor für Leukämiediagnostik, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistr. 15, D81377, München, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s15006-020-0389-8DOI Listing

A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Psychother Psychosom 2020 14;89(4):200-214. Epub 2020 Apr 14.

Department of Internal Medicine, Dermatology and Psychiatry, University of La Laguna, San Cristóbal de La Laguna, Spain.

Using Richardson and Davidson's model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (TRS), which may be improved in patients who adhere to clozapine; (2) findings that clozapine is the best treatment for TRS (according to efficacy, effectiveness and well-being); and (3) potential for clozapine to cause vulnerabilities, including potentially lethal adverse drug reactions such as agranulocytosis, pneumonia, and myocarditis. Rational use requires: (1) modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, (2) the use of clozapine levels for personalizing dosing, and (3) the use of slow and personalized titration. This may make clozapine as safe as possible and contribute to increased life expectancy and well-being. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206357PMC

Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series.

Int Clin Psychopharmacol 2020 Apr 8. Epub 2020 Apr 8.

Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Yamaguchi, Japan.

Clozapine is an atypical antipsychotic known to cause multiple hematologic abnormalities, most seriously agranulocytosis, but also notably eosinophilia. It is considered as an allergic reaction with a spontaneous remission, however, sometimes, it may predict subsequent major inflammatory complications. The aim of this study was to investigate the relationship between clozapine usage and drug-induced pneumonia based on characteristic respiratory symptoms and radiological findings, retrospectively in 69 Japanese treatment-resistant schizophrenia patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/YIC.0000000000000311DOI Listing

[Cyclic neutropenia: a case report].

Authors:
Y Liu J Fu X B Guan

Zhonghua Kou Qiang Yi Xue Za Zhi 2020 Apr;55(4):264-265

Department of Oral Medicine, Capital Medical University School of Stomatology, Beijing 100050, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112144-20191114-00410DOI Listing

[Idiosyncratic drug-induced agranulocytosis: 7 year-analysis in a French university hospital].

Ann Pharm Fr 2020 May 10;78(3):230-241. Epub 2020 Feb 10.

Centre régional de pharmacovigilance, CHU de Grenoble-Alpes, 38000 Grenoble, France.

Introduction: Idiosyncratic drug-induced agranulocytosis is a rare but potentially serious haematological disorder. The pathophysiological mechanisms are complex and poorly understood. We aimed at investigating agranulocytosis drug related causes from the myelograms with "myeloid maturation arrest" performed in our university hospital over the last seven years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharma.2020.02.004DOI Listing

Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2020 May 3;149:102922. Epub 2020 Mar 3.

Department of Emergency Medicine, University of Ottawa, Ottawa, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.

We compared the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for identifying serious complications in febrile neutropenia patients. We searched MEDLINE, PubMed, EMBASE, and Cochrane Database of Systematic Reviews from inception to March 19, 2019. Two reviewers independently screened citations, extracted data, and assessed quality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2020.102922DOI Listing

Clinical experience of treating Graves' hyperthyroidism complicated with malignancy-The possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia.

Endocr J 2020 Apr 2. Epub 2020 Apr 2.

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

The treatment of Graves' hyperthyroidism (GD) complicated with malignancy is challenging, as anti-thyroid thionamide drugs (ATDs) and anti-cancer chemotherapy are both associated with a risk of neutropenia. Treatment with conventional ATDs, radioactive iodine (RAI) or potassium iodide (KI) was attempted in 8 patients with malignancy (34-80 years of age; 2 males and 6 females) in whom GD had been fortuitously diagnosed during a detailed systematic examination. Three patients requiring surgery were initially treated conventionally with methylmercaptoimidazole (MMI), MMI and KI or RAI (group A; one patient each). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.EJ20-0016DOI Listing

Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Mycoses 2020 Jul 12;63(7):653-682. Epub 2020 May 12.

Division of Haematology & Oncology, Department of Internal Medicine, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany.

Background: Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects.

Objectives: Since the last edition of recommendations for 'Treatment of invasive fungal infections in cancer patients' of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possible invasive fungal diseases (IFDs) towards pre-emptive therapy of probable IFD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/myc.13082DOI Listing

Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer.

Anticancer Res 2020 Apr;40(4):2379-2386

Department of Pharmacy, Gifu University Hospital, Gifu, Japan.

Background/aim: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin remains unclear. We investigated the association between creatinine clearance (Ccr), a marker of renal function, and the toxicity and efficacy of oxaliplatin in patients with metastatic colorectal cancer (mCRC).

Patients And Methods: Patients with mCRC who received oxaliplatin-based chemotherapy as first-line treatment were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14207DOI Listing